EAU26 Afternoon Dialogue | Prof. Kan Gong: Large-Scale Chinese VHL Cohort Reveals Distinct Mutation Patterns and Clinical Implications 

EAU26 Afternoon Dialogue | Prof. Kan Gong: Large-Scale Chinese VHL Cohort Reveals Distinct Mutation Patterns and Clinical Implications 

The 2026 European Association of Urology Annual Congress (EAU26), held in London, once again served as a premier platform showcasing cutting-edge advances in urologic oncology. At this year’s meeting, Prof. Kan Gong and his team from Peking University First Hospital presented a series of impactful studies focusing on von Hippel–Lindau (VHL) syndrome–associated renal cell carcinoma in the Chinese population.
Voices from China at the EBMT Annual Meeting丨Prof. Yue Lu / Prof. Fang Xu: Efficacy and Safety of Blinatumomab as Part of Induction or Early Consolidation Therapy in Newly Diagnosed B-Cell Acute Leukemia

Voices from China at the EBMT Annual Meeting丨Prof. Yue Lu / Prof. Fang Xu: Efficacy and Safety of Blinatumomab as Part of Induction or Early Consolidation Therapy in Newly Diagnosed B-Cell Acute Leukemia

Blinatumomab, a CD19/CD3 bispecific antibody, has demonstrated clear efficacy in relapsed/refractory and MRD-positive B-cell acute lymphoblastic leukemia (B-ALL). Its integration into frontline therapy for newly diagnosed patients is now being actively explored and may reshape treatment paradigms.
Voices from China at the EBMT Annual Meeting丨Prof. Peihua Lu / Prof. Wei Zhao: Letermovir Prophylaxis Reshapes Early Immune Reconstitution and CMV/EBV Reactivation Dynamics After Allogeneic HSCT

Voices from China at the EBMT Annual Meeting丨Prof. Peihua Lu / Prof. Wei Zhao: Letermovir Prophylaxis Reshapes Early Immune Reconstitution and CMV/EBV Reactivation Dynamics After Allogeneic HSCT

The 52nd EBMT Annual Meeting was held in Madrid, Spain, from March 22 to 25, 2026. As one of the most influential global conferences in hematopoietic stem cell transplantation, the meeting showcased cutting-edge research and the latest clinical advances in the field.
Voices from China at the EBMT Annual Meeting丨Prof. Hui Wang: An Early Myeloid Stem/Progenitor Cell–Based Immunophenotypic Panel Enables Rapid and Efficient Differentiation of APL from APL-Like AML

Voices from China at the EBMT Annual Meeting丨Prof. Hui Wang: An Early Myeloid Stem/Progenitor Cell–Based Immunophenotypic Panel Enables Rapid and Efficient Differentiation of APL from APL-Like AML

The 52nd EBMT Annual Meeting was held in Madrid, Spain, from March 22 to 25, 2026. The conference focused on the latest advances in clinical hematology and hematopoietic stem cell transplantation, promoting continued progress in both clinical practice and translational research.
Voices from China at the EBMT Annual Meeting丨Liu Deyan / Liu Xiaohong: Efficacy of Gemtuzumab Ozogamicin in Relapsed/Refractory AML After Allo-HSCT and Outcomes of Bridging to Second/Third Transplantation — A Retrospective Study

Voices from China at the EBMT Annual Meeting丨Liu Deyan / Liu Xiaohong: Efficacy of Gemtuzumab Ozogamicin in Relapsed/Refractory AML After Allo-HSCT and Outcomes of Bridging to Second/Third Transplantation — A Retrospective Study

Relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) carries an extremely poor prognosis, particularly in patients with high CD33 expression who are refractory to conventional salvage therapies, where treatment options remain very limited.
Insights from the EBMT Annual Meeting丨Prof. Yue Lu on Post-Transplant Relapse in Acute Leukemia: Second Transplantation and Donor Optimization Strategies

Insights from the EBMT Annual Meeting丨Prof. Yue Lu on Post-Transplant Relapse in Acute Leukemia: Second Transplantation and Donor Optimization Strategies

Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains one of the major barriers to long-term survival in acute leukemia. With the rapid development of targeted therapies, hypomethylating agents, and immunotherapies such as CAR-T, salvage treatment options have expanded considerably. As a result, more patients are now able to achieve remission again and proceed to subsequent consolidation strategies.
Prof. Jennifer King: Cabozantinib Breaks Through in Relapsed/Refractory Germ Cell Tumors, Patient-Centered Care Is the Future Core Direction

Prof. Jennifer King: Cabozantinib Breaks Through in Relapsed/Refractory Germ Cell Tumors, Patient-Centered Care Is the Future Core Direction

At the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), breakthroughs in the treatment of relapsed and refractory germ cell tumors emerged as a major focus in the field of genitourinary oncology. Oncology Frontier – UroStream invited Prof. Jennifer King from Indiana University School of Medicine for an in-depth interview, discussing her team’s key research findings, evolving trends in genitourinary cancers, and future directions in clinical development.
Prof. Enrique Gallardo: Final OS Results from PEACE-3 Trial — Enzalutamide Plus Radium-223 Reshapes the mCRPC Treatment Landscape

Prof. Enrique Gallardo: Final OS Results from PEACE-3 Trial — Enzalutamide Plus Radium-223 Reshapes the mCRPC Treatment Landscape

The 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) has successfully concluded, bringing forward several landmark advances in prostate cancer. Among them, the final overall survival (OS) results from the EORTC 1333/PEACE-3 trial represent a major milestone in the management of metastatic castration-resistant prostate cancer (mCRPC) with bone metastases.
Voice of China at EAU | Prof. Haixing Mai’s Team (PLA General Hospital): High-Level Evidence for Minimally Invasive Management of 2–4 cm Lower Pole Renal Stones 

Voice of China at EAU | Prof. Haixing Mai’s Team (PLA General Hospital): High-Level Evidence for Minimally Invasive Management of 2–4 cm Lower Pole Renal Stones 

From March 13–16, 2026, the 41st Annual Congress of the European Association of Urology (EAU26) was held at the ExCeL International Convention Centre in London, UK. As the largest and one of the most authoritative academic events in urology worldwide, the congress brought together leading experts from over 100 countries and regions to discuss cutting-edge advances and drive innovation in the field. At a featured scientific session, Prof. Ke Sun, representing the team led by Prof. Haixing Mai from the Chinese PLA General Hospital (301 Hospital), presented a study entitled: